Drug news
NICE rejects both Erbitux (cetuximab) from Merck Serono and Vectibix (panitumumab) from Amgen as first line treatments for colorectal cancer.
The National Institute for Health and Care Excellence (NICE) has published interim guidance after reviewing both personalised therapies, Vectibix (panitumumab) and Erbitux (cetuximab), as first line treatments for colorectal cancer. NICE does not see the drugs as a cost effective use of resources as first line therapy with chemotherapy for the RAS wild-type metastatic colorectal cancer. Both drugs will be available to the NHS through the Cancer Drugs Fund until March 2016.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.